PVLA — PALVELLA THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1583648 ·
Last close
$144.35
Market Cap
$2.11B
52W High
$179.95
52W Low
$72.22
ADV30
265,079
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -22,726,000 | -24,643,000 | 239,402,000 | 193,297,000 | 41,478,000 |
| Jun 2026 | 0 | — | -21,405,000 | -21,870,000 | 253,510,000 | 187,803,000 | 36,643,000 |
| Mar 2026 | 0 | — | -14,855,000 | -15,767,000 | 263,759,000 | 206,394,000 | 31,446,000 |
| Dec 2025 | 0 | — | -11,304,000 | -12,714,000 | 59,559,000 | 57,982,000 | 31,576,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-36,513,000
Investing CF
$-62,472,000
Financing CF
$216,204,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.61
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-173,087,000
Inventory
—
Receivables
$0
ST Investments
$62,781,000
EBIT TTM
$-54,100,000
Pretax Income TTM
$-61,696,000
Interest Exp TTM
$7,596,000
Analysts
15
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -38,602,000 | -41,715,000 | 59,559,000 | 31,576,000 | 27,983,000 | -25,006,000 |
| Dec 2024 | 0 | -14,095,000 | -17,434,000 | 88,234,000 | 25,627,000 | 62,607,000 | -10,840,000 |
| Dec 2023 | 0 | -11,869,000 | 18,691,000 | 7,548,000 | 11,428,000 | -3,880,000 | -13,703,000 |
| Dec 2022 | 0 | -18,040,000 | -27,552,000 | 16,524,000 | 39,698,000 | -23,174,000 | -14,840,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-61,696,000
OpCashFlow TTM
—
Assets (Latest)
$253,510,000
Forward EPS
$-8.19
Max Pain — expiry 2026-12-18
max pain strike: $135.00 · spot: $146.58 · call oi: 1,046 · put oi: 35Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AUPH | Aurinia Pharmaceuticals Inc. | $2.06B | $15.40 | — |
| PRGO | PERRIGO Co plc | $2.19B | $15.76 | — |
| IMNM | Immunome Inc. | $2.03B | $17.18 | — |
| BHVN | Biohaven Ltd. | $2.00B | $13.24 | — |
| GRFS | Grifols SA | $2.23B | $8.63 | — |
News headlines (Yahoo Finance, 1h cache)
Palvella Therapeutics to Host Webcast to Introduce New QTORIN™ Program
2026-11-18 22:00 · Yahoo
Palvella Therapeutics Inc (PVLA) (Q3 2026) Earnings Call Highlights: FDA Priority Review, $236. ...
2026-11-05 23:16 · Yahoo
Palvella Therapeutics, Inc. Q3 2026 Earnings Call Summary
2026-11-05 22:30 · Yahoo
What Palvella Therapeutics (PVLA) Said on Its Q3 Earnings Call
2026-11-05 22:14 · Yahoo
Palvella (PVLA) Q3 2026 Earnings Call Transcript
2026-11-05 19:33 · Yahoo
Palvella Therapeutics: Q3 Earnings Snapshot
2026-11-05 12:48 · Yahoo
Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-05 12:30 · Yahoo
Palvella Therapeutics to Participate in the Stifel 2026 Healthcare Conference
2026-11-03 12:30 · Yahoo
Palvella Therapeutics to Host Third Quarter 2026 Financial Results and Corporate Update Conference Call on November 5, 2026
2026-10-29 11:30 · Yahoo
Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set
2026-10-28 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.